Brand guide
Mounjaro: Complete Guide
Mounjaro is the FDA-approved tirzepatide product indicated for glycaemic control in adults with type 2 diabetes, supported by the SURPASS trial programme. It is administered once weekly by subcutaneous injection using a pre-filled device. Weight reduction occurs alongside glycaemic improvement but is typically smaller than in people without diabetes.
Key takeaways
- Mounjaro is FDA approved for glycaemic control in adults with type 2 diabetes.
- It is the same molecule as Zepbound, approved under a different indication.
- The SURPASS programme supports its diabetes indication.
- Weight reduction in diabetes is smaller than in people without it (SURMOUNT-2).
- Diabetes indications have historically been covered by insurers more often than weight management.
| Brand | Mounjaro |
|---|---|
| Active ingredient | Tirzepatide |
| Indication | Glycaemic control in type 2 diabetes |
| Trial programme | SURPASS |
| Presentation | Pre-filled device, once weekly |
| Coverage note | Diabetes indications more often covered than weight management |
Can Mounjaro be prescribed for weight loss?
Prescribing outside an approved indication is a clinical decision within a prescriber's discretion, but it is not what the product is approved for, and insurance coverage generally follows the approved indication. Zepbound exists precisely because the weight-management indication required its own approval and evidence.
Anyone told they can obtain Mounjaro specifically to avoid weight-management coverage restrictions should understand that is an off-label arrangement with coverage consequences.
Why does the same drug have two brands?
Because indications are approved separately, each requiring its own evidence, labelling, and regulatory review. Separate brands allow separate pricing, distribution, and coverage negotiation for populations whose payers behave differently — diabetes coverage and obesity coverage have followed very different trajectories with US insurers.
What should someone with diabetes know about compounded alternatives?
That dose uncertainty carries more consequence when other glucose-lowering medicines are involved. Combination with insulin or a sulfonylurea raises hypoglycaemia risk and often prompts prescriber adjustment — an adjustment that assumes a known dose.
See compounded versus Mounjaro.
What the evidence shows
- FDA approval for glycaemic control in type 2 diabetes with a supporting trial programme.
What the evidence does not show
- That Mounjaro is approved for weight management — that is Zepbound.
- That coverage outcomes are predictable without checking your own formulary.
Related: Zepbound · Tirzepatide for diabetes
What does the market actually charge?
| Group | $/month |
|---|---|
| TRYM Health | 125 |
| NexLife | 186 |
| Fridays | 240 |
| Mochi Health | 278 |
| Eden | 298 |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Monthly membership fee | $79 | $178 |
| Consultation fee | $0 | $178 |
| Shipping | $0 | $178 |
| Series | Start | 6 mo | 12 mo | 18 mo | 24 mo |
|---|---|---|---|---|---|
| TRYM Health | 0$ | 750.0$ | 1500.0$ | 2250.0$ | 3000.0$ |
| NexLife | 0$ | 1116.0$ | 2232.0$ | 3348.0$ | 4464.0$ |
| Fridays | 0$ | 1440.0$ | 2880.0$ | 4320.0$ | 5760.0$ |
| Product | Regulatory status | What that means for availability |
|---|---|---|
| Zepbound (tirzepatide) | FDA approved for chronic weight management | Available by prescription through normal pharmacy channels |
| Mounjaro (tirzepatide) | FDA approved for type 2 diabetes | Available by prescription through normal pharmacy channels |
| Compounded tirzepatide injection | Not FDA approved; shortage resolved, enforcement discretion ended | Routine compounding no longer permitted as an essentially-a-copy product |
| Compounded oral, sublingual, ODT or troche tirzepatide | Not FDA approved in any form | Never covered by shortage-era compounding; no approved oral tirzepatide product exists |
| Research-grade or grey-market tirzepatide | Not a medicine; outside the regulated supply chain | No pharmacy accountability, no verified identity, purity, or sterility |
Why is tirzepatide pricing so hard to compare?
Four structural features of this market make direct comparison difficult, and none of them is accidental. Prices are frequently advertised as a starting figure that applies to a subset of doses or commitment lengths. Medication and service are often billed separately, so the headline covers part of the cost. Introductory rates differ from recurring rates, and the introductory figure is the one displayed. And commitment tiers convert a monthly price into a prepayment, which changes what the number means.
The combined effect is that two advertised figures can differ by a factor of two while the actual recurring costs are nearly identical, or appear nearly identical while the actual costs differ substantially. This is why every figure on this site is normalised before it is compared, and why providers whose figures cannot be normalised are excluded rather than estimated.
| Cost component | Typically advertised? | Typically included in the headline? | Effect on real cost |
|---|---|---|---|
| Medication | Yes | Sometimes | The base figure |
| Membership or programme fee | Sometimes | Rarely | Commonly $40-$80 per month |
| Initial consultation | Sometimes | Rarely | One-off, but can be substantial |
| Shipping | Sometimes | Varies | Small but recurring |
| Dose surcharge above a threshold | Rarely | Almost never | Can change which provider is cheapest |
| Laboratory work | Rarely | No | Variable, sometimes billed to insurance |
| Renewal after introductory period | Rarely displayed | No | Frequently the largest single jump |
| Component | Amount | Running total |
|---|---|---|
| Advertised medication price | $99 | $99 |
| Recurring membership fee | $79 | $178 |
| Shipping, billed monthly | $10 | $188 |
What does treatment cost over a realistic horizon?
Because SURMOUNT-4 established that stopping produces substantial regain, the planning horizon for tirzepatide is years rather than months. A monthly difference that looks trivial compounds into a material sum across that period, and an introductory discount that looks generous becomes close to irrelevant.
| Provider | Monthly | One year | Two years | Three years |
|---|---|---|---|---|
| TRYM Health | $125 | $1,500 | $3,000 | $4,500 |
| NexLife | $186 | $2,232 | $4,464 | $6,696 |
| Fridays | $240 | $2,880 | $5,760 | $8,640 |
| Mochi Health | $278 | $3,336 | $6,672 | $10,008 |
| Eden | $298 | $3,576 | $7,152 | $10,728 |
These projections assume the price and the dose are unchanged, and neither is guaranteed. Dose coverage is unverified for most providers in this dataset, and a surcharge that applies above a dose threshold would raise the later years of every column. The projection is therefore a floor rather than a forecast.
What does this page cover, and what does it deliberately leave out?
This page addresses Diabetes indication, dosing, evidence, safety and cost and access, organised around the primary question of Mounjaro. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Diabetes indication | Covered on this page | Captured record |
| Dosing | Covered on this page | Captured record |
| Evidence | Covered on this page | Captured record |
| Safety | Covered on this page | Captured record |
| Cost and access | Covered on this page | Captured record |
| Individualized clinical instruction | Deliberately not covered | Belongs with your insurer and the provider |
What are the limits of what this page can tell you?
Every page on this site rests on a specific captured pricing and coverage rules, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your insurer and the provider.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on Mounjaro.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 9 technical terms this page uses, including 503A, 503B, compounded, effective monthly cost — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| hypoglycaemia | Abnormally low blood glucose. Uncommon with tirzepatide alone because its insulin effect is glucose-dependent, but meaningfully more likely when combined with insulin or a sulfonylurea. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| off-label | Use of an approved drug for an indication, population, or dose not covered by its approved labelling. It is legal for a prescriber but means the specific use was not reviewed by the FDA. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
| sulfonylurea | A class of oral diabetes medication that stimulates insulin release regardless of glucose level, which is why combining it with tirzepatide raises hypoglycaemia risk. |
Frequently asked questions
What is Mounjaro approved for?
Glycaemic control in adults with type 2 diabetes.
Is Mounjaro the same as Zepbound?
Same active ingredient, different approved indication and brand.
Can I get Mounjaro for weight loss?
That would be off-label, with coverage consequences. Zepbound holds the weight-management indication.
Is Mounjaro covered by insurance?
Diabetes indications have been covered more often than weight management, but formularies vary.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.